Clinical Resources Dianne Trim 6/23/26 Dianne Trim 6/23/26 Comparative Effectiveness of Placental Allografts in the Treatment of Diabetic Lower Extremity Ulcers and Venous Leg Ulcers in U.S. Medicare Beneficiaries Read More Dianne Trim 6/23/26 Dianne Trim 6/23/26 Real-world outcomes of a placenta-based tissue product versus standard of care for lower extremity diabetic ulcers: A Medicare cohort study Read More Dianne Trim 6/23/26 Dianne Trim 6/23/26 Calciphylaxis-associated pannicular wounds in end-stage renal disease: Recurrent disease, massive adiposenecrosis, and eventual resolution through multidisciplinary management Read More Dianne Trim 6/23/26 Dianne Trim 6/23/26 Recommendations to inform National Coverage Determination development for skin substitutes in hard-to-heal wounds Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Early reported effects of the 2026 CMS Physician Fee Schedule on patient access to CAMPs in wound care: a national clinician and practice survey Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Treatment patterns and outcomes of Medicare enrollees who developed venous leg ulcers It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 The influence of adequate debridement and placental-derived allografts on diabetic foot ulcers It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Specialty-specific quality measures needed to improve outcomes in wound care It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) in Stage 3 pressure injury ulcers: A matched Medicare claims analysis (2016–2024) It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 The hidden costs of limiting access: clinical and economic risks ofMedicare’s future effective cellular, acellular, and matrix-like products (CAMPs) Local Coverage Determination It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Safeguarding access, fiscal responsibility, and innovation: a comprehensive reimbursement framework for CAMPs to preserve the Medicare Trust Fund It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Rethinking regulatory tiers: Medicare real-world evidence shows CAMP outcomes are independent of FDA regulatory classification It All Begins Here Read More Dianne Trim 6/15/26 Dianne Trim 6/15/26 Impact of Hyperbaric Oxygen on More Advanced Wagner Grades 3 and 4 Diabetic Foot Ulcers: Matching Therapy to Specific Wound Conditions It All Begins Here Read More Dianne Trim 5/28/19 Dianne Trim 5/28/19 Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015–2018) It All Begins Here Read More
Dianne Trim 6/23/26 Dianne Trim 6/23/26 Comparative Effectiveness of Placental Allografts in the Treatment of Diabetic Lower Extremity Ulcers and Venous Leg Ulcers in U.S. Medicare Beneficiaries Read More
Dianne Trim 6/23/26 Dianne Trim 6/23/26 Real-world outcomes of a placenta-based tissue product versus standard of care for lower extremity diabetic ulcers: A Medicare cohort study Read More
Dianne Trim 6/23/26 Dianne Trim 6/23/26 Calciphylaxis-associated pannicular wounds in end-stage renal disease: Recurrent disease, massive adiposenecrosis, and eventual resolution through multidisciplinary management Read More
Dianne Trim 6/23/26 Dianne Trim 6/23/26 Recommendations to inform National Coverage Determination development for skin substitutes in hard-to-heal wounds Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Early reported effects of the 2026 CMS Physician Fee Schedule on patient access to CAMPs in wound care: a national clinician and practice survey Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Treatment patterns and outcomes of Medicare enrollees who developed venous leg ulcers It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 The influence of adequate debridement and placental-derived allografts on diabetic foot ulcers It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Specialty-specific quality measures needed to improve outcomes in wound care It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) in Stage 3 pressure injury ulcers: A matched Medicare claims analysis (2016–2024) It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 The hidden costs of limiting access: clinical and economic risks ofMedicare’s future effective cellular, acellular, and matrix-like products (CAMPs) Local Coverage Determination It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Safeguarding access, fiscal responsibility, and innovation: a comprehensive reimbursement framework for CAMPs to preserve the Medicare Trust Fund It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Rethinking regulatory tiers: Medicare real-world evidence shows CAMP outcomes are independent of FDA regulatory classification It All Begins Here Read More
Dianne Trim 6/15/26 Dianne Trim 6/15/26 Impact of Hyperbaric Oxygen on More Advanced Wagner Grades 3 and 4 Diabetic Foot Ulcers: Matching Therapy to Specific Wound Conditions It All Begins Here Read More
Dianne Trim 5/28/19 Dianne Trim 5/28/19 Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015–2018) It All Begins Here Read More
